反応式
[Cl-].COC[P+](C1C=CC=CC=1)(C1C=CC=CC=1)C1C=CC=CC=1.FC1C=C(OC)C(F)=CC=1N1CCC(=O)CC1.[Br-].[CH2:42]([P+](C1C=CC=CC=1)(C1C=CC=CC=1)C1C=CC=CC=1)[CH2:43][C:44]1[CH:49]=[CH:48][CH:47]=[CH:46][CH:45]=1.[F:69][C:70]1[CH:75]=[C:74]([O:76][CH3:77])[C:73]([F:78])=[CH:72][C:71]=1[N:79]1[CH2:84][CH2:83][CH:82]([CH:85]=O)[CH2:81][CH2:80]1>>[F:69][C:70]1[CH:75]=[C:74]([O:76][CH3:77])[C:73]([F:78])=[CH:72][C:71]=1[N:79]1[CH2:84][CH2:83][CH:82](/[CH:85]=[CH:42]\[CH2:43][C:44]2[CH:45]=[CH:46][CH:47]=[CH:48][CH:49]=2)[CH2:81][CH2:80]1参加物
5
実験手順
Production Example 74 was repeated except that methoxymethyltriphenylphosphonium chloride and 1-(2,5-difluoro-4-methoxyphenyl)piperidin-4-one were replaced with phenethyltri-phenylphosphonium bromide (133 mg) and 1-(2,5-difluoro-4-methoxyphenyl)-4-piperidinecarbaldehyde (35 mg), respectively, and the resulting crude product was purified on TLC (developer, hexane: ethyl acetate=10:1) to provide (Z)-1-(2,5-difluoro-4-methoxyphenyl)-4-(3-phenyl-1-propen-1-yl)piperidine (37 mg).
後処理
- customrespectively, and the resulting crude product was purified on TLC (developer, hexane: ethyl acetate=10:1)
出典と根拠
- ORDレコード
- ord-67f811637d1746b9803a3db98e54a5be
- 出典データセット
- uspto-grants-2008_11
- 特許番号
- US07449466B2
関連ノート
読み込み中…